Kymera 
KYMR is a clinical-stage biotech advancing oral targeted protein degradation therapies across autoimmune disease, inflammation, and oncology—positioned as a leader in next-gen small-molecule immunology.
Key Catalysts
KT-621 (STAT6 degrader) = Flagship Program: A potential first-in-class oral STAT6 degrader, advancing through Phase 2b in atopic dermatitis and eosinophilic asthma—large markets where oral convenience and targeted mechanism can drive adoption.
Next Wave Pipeline: KT-579 (IRF5 degrader) is entering Phase 1, with initial data expected 2H 2026, adding a meaningful catalyst and expanding Kymera’s footprint in inflammatory biology.
Platform Validation + Funding Strength: Collaboration with Gilead Sciences provides external validation and non-dilutive support, strengthening balance-sheet flexibility and execution capacity.
Why It Matters
✅ Oral degraders can offer biologic-like selectivity with pill convenience
✅ Multiple independent shots on goal across immunology targets
✅ Strong partner backing reduces financing pressure
Investment Outlook
Bullish above: $74–$75
Upside target: $110–$115, driven by KT-621 Phase 2b progress, KT-579 clinical entry, and platform validation.
KYMR is a clinical-stage biotech advancing oral targeted protein degradation therapies across autoimmune disease, inflammation, and oncology—positioned as a leader in next-gen small-molecule immunology.Key Catalysts
KT-621 (STAT6 degrader) = Flagship Program: A potential first-in-class oral STAT6 degrader, advancing through Phase 2b in atopic dermatitis and eosinophilic asthma—large markets where oral convenience and targeted mechanism can drive adoption.
Next Wave Pipeline: KT-579 (IRF5 degrader) is entering Phase 1, with initial data expected 2H 2026, adding a meaningful catalyst and expanding Kymera’s footprint in inflammatory biology.
Platform Validation + Funding Strength: Collaboration with Gilead Sciences provides external validation and non-dilutive support, strengthening balance-sheet flexibility and execution capacity.
Why It Matters
✅ Oral degraders can offer biologic-like selectivity with pill convenience
✅ Multiple independent shots on goal across immunology targets
✅ Strong partner backing reduces financing pressure
Investment Outlook
Bullish above: $74–$75
Upside target: $110–$115, driven by KT-621 Phase 2b progress, KT-579 clinical entry, and platform validation.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.